Welcome to the latest edition of our weekly EuroBiotech Report. A who's who of Big Pharma companies joined a European public-private consortium this week to develop and test new economic models of antibiotic R&D. The goal is to make antibiotic R&D economically attractive again. Karo Bio was forced to assess the financial viability of its R&D operation after Pfizer decided to move a collaboration into its own labs. The Swedish biotech is preparing to lay off staff. NeuroSearch has long since shed its staff and is now offloading the last of its assets. Saniona picked up two of its early-phase drugs in a no-cash deal. Advent Life Sciences raised £145.5 million ($235 million) to invest in biotechs on both sides of the Atlantic. British nonprofits Cancer Research UK and Leukaemia & Lymphoma Research teamed up to take blood cancer candidates out of the lab and up to Phase II trials. And more. Read the full report >>
A few things struck us while gathering this year's class of the Fierce 15, our 12th annual take on some of the most noteworthy private biotech upstarts making headway these days. First, you'll find a higher than usual accumulation of early-stage companies in the group. And it's not hard to see why. Once the IPO window opened in early 2013, we saw a whole slew of earlier winners jump through--many like bluebird and Agios winning some extraordinary returns for investors. By the end of last year we were beginning to see plenty of other newcomers make the move as well, definitely winnowing out the number of more advanced companies to select from.
Carving out a successful career in biopharma isn't easy, for men or women. The failure rate of experimental drugs is astronomically high. And just because a company wins an approval is no guarantee of success, particularly in this increasingly challenging market. At the same time, though, it was no great feat to find 15 women who have been doing some amazing things. Check out the special report >>
Welcome to the hall of shame, where blockbuster drug projections go to die. Here you'll find some drugs that clearly should never have wound up in Phase III to begin with, a few that were actually steered back to the clinic in a doomed attempt to mine something positive after wasting millions on clinical trials and a couple of notable exceptions that may have helped advance the field by exploring the outer limits of new drug technology. Read more >>
It's better to be lucky than smart, but to be among the best life sciences investors it helps to be both. We've compiled a list of public company investors who have managed to outperform the NASDAQ Biotechnology Index (NBI), mostly driven by their participation in some of the top biotech performers this year.
POPULAR COMMENT THREADS
In an uncommon move, the FDA has publicly weighed in on an in-development drug, clarifying the status of Sarepta Therapeutics' closely watched Duchenne muscular dystrophy treatment eteplirsen in light of an earlier setback that tanked the biotech's shares. Read more >>
Novo Nordisk has broken ground on a new R&D shop in its native Denmark, plotting a $130 million project that will expand its wide footprint in diabetes research.
The band behind FerroKin BioSciences, a pioneer of the virtual biotech model, has gotten back together to take a stab at epigenetics, raising $26.5 million from some A-list investors to develop new treatments for orphan diseases.
A panel of FDA advisers voted in favor of approving Daiichi Sankyo's irregular heartbeat treatment edoxaban, heralding its ability to break up blood clots and improving the company's odds of finally launching the drug in the U.S.
Impax Laboratories is slashing its R&D payroll and moving away from early-stage research, a move designed to save cash in the midst of a costly transition.
Novartis has leased a sizable outpost in the Philadelphia suburbs, according to a local report, settling into the area as it works with University of Pennsylvania researchers on a promising new approach to treating cancer.
From Our Sister Sites
U.K. researchers have hit upon a drug combination that appears to combat lung cancer by triggering self-destruction in tumor cells.
Amid efforts to counter the deadly Ebola outbreak, researchers and companies are homing in on rapid mobile tests as a more effective way to prevent the disease's spread.